Inflammatory events during murine squamous cell carcinoma development

Journal of Inflammation (United Kingdom)

Volumn 9, Issue , 2012, Pages

  Gasparoto, Thais Helena ^a   De Oliveira, Carine Ervolino ^a   De Freitas, Luisa Thomazini ^a   Pinheiro, Claudia Ramos ^a   Ramos, Rodrigo Nalio ^a   Da Silva, André Luis ^a   Garlet, Gustavo Pompermaier ^a   Da Silva, João Santana ^a   Campanelli, Ana Paula ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cytokines; Elastase; Inflammatory cells; Myeloperoxidase; Nitric oxide

Indexed keywords

ELASTASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; MYELOPEROXIDASE; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; INFLAMMATION; LEUKOCYTE ACTIVATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALIA; MURINAE;

EID: 84869880961     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-9-46     Document Type: Article

References (75)

1. T cell exhaustion. Wherry EJ, Nat Immunol 2011 12 492 499 21739672
2. Myeloperoxidase: the yin and yang in tumour progression. Mika D, Guruvayoorappan C, J Exp Ther Oncol 2011 9 93 100 21699016
3. Environment, inflammation, and cancer. Sansone P, Bromberg J, Cur Opin Gen Develop 2011 21 80 85 10.1016/j.gde.2010.11.001
4. Immunity, inflammation, and cancer. Grivennikov SI, Greten FR, Karin M, Cell 2010 140 883 899 10.1016/j.cell.2010.01.025 20303878
5. Reactive oxygen species in tumor metastasis. Nishikawa M, Cancer Lett 2008 266 53 59 10.1016/j.canlet.2008.02.031 18362051
6. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, Halliwell B, Biochem J 1996 313 17 29 8546679 (Pubitemid 26013419)
7. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Nishikawa M, Hashida M, Takakura Y, Adv Drug Deliv Rev 2009 61 319 326 10.1016/j.addr.2009.01.001 19385054
8. Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates. Lonkar P, Dedon PC, Int J Cancer 2011 128 1999 2009 10.1002/ijc.25815 21387284
9. Chronic inflammation and oxidative stress in human carcinogenesis. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C, Int J Cancer 2007 121 2381 2386 10.1002/ijc.23192 17893868 (Pubitemid 350022406)
10. The phagocytes: neutrophils and monocytes. Dale DC, Boxer L, Liles WC, Blood 2008 112 935 945 10.1182/blood-2007-12-077917 18684880
11. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Stiborová M, Rupertová M, Frei E, Biochim Biophys Acta 2011 1814 175 185 10.1016/j.bbapap.2010.05.016 20576524
12. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Sun Z, Yang P, Lancet Oncol 2004 5 182 190 10.1016/S1470-2045(04)01414-7 15003202 (Pubitemid 38262851)
13. Neutrophil elastase and cancer. Sato T, Takahashi S, Mizumoto T, Harao M, Akizuki M, Takasugi M, Fukutomi T, Yamashita J, Surg Oncol 2006 15 217 222 10.1016/j.suronc.2007.01.003 17320378 (Pubitemid 46771195)
14. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Pai SI, Westra WH, Annu Rev Pathol 2009 4 49 70 10.1146/annurev.pathol.4.110807.092158 18729723
15. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
16. Sun exposure and skin disease. Taylor CR, Sober AJ, Annu Rev Med 1996 47 181 191 10.1146/annurev.med.47.1.181 8712772 (Pubitemid 26138883)
17. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Fortina AB, Piaserico S, Caforio AL, Abeni D, Alaibac M, Angelini A, Iliceto S, Peserico A, Arch Dermatol 2004 140 1079 1085 10.1001/archderm.140.9.1079 15381547 (Pubitemid 39223115)
18. Infiltration by inflammatory cells required for solar-simulated ultraviolet radiation enhancement of skin tumor growth. Sluyter R, Halliday GM, Cancer Immunol Immunother 2001 50 151 156 10.1007/PL00006685 11419182 (Pubitemid 32480559)
19. Body fluid biomarkers for early detection of head and neck squamous cell carcinomas. Lee KD, Lee HS, Jeon CH, Anticancer Res 2011 31 1161 1167 21508360
20. Chemotaxis in cancer. Roussos ET, Condeelis JS, Patsialou A, Nat Rev Cancer 2011 11 573 587 10.1038/nrc3078 21779009
21. Role of cytokines in head and neck squamous cell carcinoma. Pries R, Nitsch S, Wollenberg B, Expert Rev Anticancer Ther 2006 6 1195 1203 10.1586/14737140.6.9.1195 17020454
22. 12-O-tetradecanoylphorbol-13-acetate-mediated systemic co-promotion in the murine skin multistage carcinogenesis protocol. Reiners JJ Jr, Pavone A, Maldve R, Fischer SM, Carcinogenesis 1993 14 411 415 10.1093/carcin/14.3.411 8453717 (Pubitemid 23152774)
23. Transgenic cyclooxygenase-2 overexpression sensitises mouse skin for carcinogenesis. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G, Proc Natl Acad Sci USA 2002 99 12483 12488 10.1073/pnas. 192323799 12221288
24. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Blumberg PM, Cancer Res 1988 48 1 8 3275491 (Pubitemid 18030320)
25. Protein kinase C and the activation of the human neutrophil NADPH-oxidase. Tauber AI, Blood 1987 69 711 720 3545319 (Pubitemid 17057445)
26. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. De Larco JE, Wuertz BR, Furcht LT, Clin Cancer Res 2004 10 4895 4900 10.1158/1078-0432.CCR-03-0760 15297389 (Pubitemid 39099762)
27. The interleukin-8 pathway in cancer. Waugh DJ, Wilson C, Clin Cancer Res 2008 14 6735 6741 10.1158/1078-0432.CCR-07-4843 18980965
28. A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. Franco M, Bustuoabad OD, di Gianni PD, Goldman A, Pasqualini CD, Ruggiero RA, Br J Cancer 1996 74 178 186 10.1038/bjc.1996.335 8688319 (Pubitemid 26254127)
29. Salivary immunity in elderly individuals presented with Candida-related denture stomatitis. Gasparoto TH, Sipert CR, de Oliveira CE, Porto VC, Santos CF, Campanelli AP, Lara VS, Gerodontology 2012 47 741 748
30. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Ziech D, Franco R, Pappa A, Panayiotidis MI, Mutat Res 2011 711 167 173 10.1016/j.mrfmmm.2011.02.015 21419141
31. Chemical basis of inflammation-induced carcinogenesis. Ohshima H, Tatemichi M, Sawa T, Arch Biochem Biophys 2003 417 3 11 10.1016/S0003-9861(03) 00283-2 12921773 (Pubitemid 36960042)
32. Oxidative stress, DNA methylation and carcinogenesis. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI, Cancer Lett 2008 266 6 11 10.1016/j.canlet.2008.02.026 18372104
33. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Ziech D, Franco R, Georgakilas AG, Georgakila S, Malamou-Mitsi V, Schoneveld O, Pappa A, Panayiotidis MI, Chem Biol Interact 2010 188 334339
34. Myeloperoxidase genetic polymorphism and lung cancer risk. London SJ, Lehman TA, Taylor JA, Cancer Res 1997 57 5001 5003 9371491 (Pubitemid 27498108)
35. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cascorbi I, Henning S, Brockmöller J, Gephart J, Meisel C, Müller JM, Loddenkemper R, Roots I, Cancer Res 2009 60 644 649
36. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F, Pharmacol Rev 2010 62 726 759 10.1124/pr.110.002733 21079042
37. Myeloperoxidase of the leukocyte of normal human blood. I. Content and localization. Schultz J, Kaminker K, Arch Biochem Biophys 1962 96 465 467 10.1016/0003-9861(62)90321-1 13909511
38. Myeloperoxidase: Friend and foe. Klebanoff SJ, J Leukoc Biol 2005 77 598 625 10.1189/jlb.1204697 15689384 (Pubitemid 40628741)
39. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, et al. J Clin Oncol 2009 27 4973 4979 10.1200/JCO.2009.21.8669 19752340
40. Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? Lanza F, Fietta A, Spisani S, Castoldi GL, Traniello S, J Clin Lab Immunol 1987 22 175 180 3039142 (Pubitemid 17115756)
41. Depressed neutrophil-mediated tumor cell cytotoxicity in subjects affected by hereditary myeloperoxidase deficiency and secondary neoplasia. Lanza F, Giuliani AL, Amelotti F, Spisani S, Traniello S, Castoldi G, Haematologica 1998 73 355 358
42. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Weitzman SA, Gordon LI, Blood 1990 76 655 663 2200535 (Pubitemid 20253278)
43. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Liotta LA, Stetler-Stevenson WG, Cancer Res 1991 51 5054 5059
44. Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Nakajima M, Chop AM, Semin Cancer Biol 1991 2 115 127 1655116
45. Collagenase and elastase production by mouse mammary adenocarcinoma primary cultures and cloned cells. Zeydel M, Nakagawa S, Biempica L, Takahashi S, Cancer Res 1986 46 6438 6445 3022919 (Pubitemid 17221798)
46. Cell associated elastase activities of rat mammary tumour cells. Grant AJ, Lerro KA, Wu CW, Bioch. Int 1990 22 1077 1084
47. Human leukocyte granule elastase: rapid isolation and characterization. Baugh RJ, Travis J, Biochemistry 1976 15 836 841 10.1021/bi00649a017 1082346
48. Mouse macrophage elastase. Banda MJ, Werb Z, Bioc J 1981 193 589 605
49. NF-kB: linking inflammation and immunity to cancer development and progression. Karin M, Greten FR, Nat Rev Immunol 2005 5 749 759 10.1038/nri1703 16175180 (Pubitemid 41400849)
50. Nuclear factor-kB in cancer development and progression. Karin M, Nature 2006 441 431 436 10.1038/nature04870 16724054 (Pubitemid 44050137)
51. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Naugler WE, Karin M, Trends Mol Med 2008 14 109 119 10.1016/j.molmed.2007.12.007 18261959
52. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Hong DS, Angelo LS, Kurzrock R, Cancer 2007 110 1911 1928 10.1002/cncr.22999 17849470 (Pubitemid 350036849)
53. Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis. Tomlins C, Storey A, Carcinogenesis 2010 31 2155 2164 10.1093/carcin/bgq200 20884685
54. The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T, Nakanishi O, Oral Dis 2011 17 462 468 10.1111/j.1601-0825.2010.01781.x 21496184
55. Radical causes of cancer. Hussain SP, Hofseth LJ, Harris CC, Nat Rev Cancer 2003 3 276 285 10.1038/nrc1046 12671666 (Pubitemid 37328863)
56. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. Huang S, Ullrich SE, Bar-Eli M, J Interferon Cytokine Res 1999 19 697 703 10.1089/107999099313532 10454339 (Pubitemid 29379811)
57. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I, Ozawa K, Cancer Res 2003 63 5091 5094 12941839 (Pubitemid 37022649)
58. A cytokine-mediated link between innate immunity, inflammation, and cancer. Lin WW, Karin M, J Clin Invest 2007 117 1175 1183 10.1172/JCI31537 17476347 (Pubitemid 46718402)
59. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Terabe M, Park JM, Berzofsky JA, Cancer Immunol Immunother 2004 53 79 85 10.1007/s00262-003-0445-0 14610620 (Pubitemid 38161213)
60. Stable IL-10: a new therapeutic that promotes tumor immunity. Teng MW, Darcy PK, Smyth MJ, Cancer Cell 2011 20 691 693 10.1016/j.ccr.2011.11.020 22172716
61. Interleukin-10 therapy-review of a new approach. Asadullah K, Sterry W, Volk HD, Pharmacol Rev 2003 55 241 269 10.1124/pr.55.2.4 12773629 (Pubitemid 36666048)
62. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL, Axelson H, Castaños-Velez E, Ljunggren HG, Malefyt RD, Granger HJ, Ziche M, et al. Blood 2000 96 2568 2573 11001913
63. IL-10 elicits IFNγ-dependent tumor immune surveillance. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, et al. Cancer Cell 2011 20 781 796 10.1016/j.ccr.2011.11. 003 22172723
64. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Alas S, Emmanouilides C, Bonavida B, Clin Cancer Res 2001 7 709 723 11297268 (Pubitemid 32707998)
65. Ammonium trichloro(dioxoethylene-o, o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, Ram Z, Orenstein A, Kershenovich A, Michowiz S, Cohen YI, Rappaport ZH, et al. Cancer Res 2004 64 1843 1852 10.1158/0008-5472.CAN-03-3179 14996748 (Pubitemid 38428710)
66. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Alas S, Bonavida B, Cancer Res 2001 61 5137 5144 11431352 (Pubitemid 32681546)
67. Interleukin-10 determines viral clearance or persistence in vivo. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB, Nat Med 2006 12 1301 1309 10.1038/nm1492 17041596 (Pubitemid 44706933)
68. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Vicari AP, Trinchieri G, Immunol Rev 2004 202 223 236 10.1111/j.0105-2896.2004. 00216.x 15546396 (Pubitemid 39576915)
69. Interleukin-17 promotes angiogenesis and tumor growth. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT, Blood 2003 101 2620 2627 10.1182/blood-2002-05-1461 12411307 (Pubitemid 36857622)
70. Transforming growth factor-β and the hallmarks of cancer. Tian M, Neil JR, Schiemann WP, Cell Signal 2011 23 951 962 10.1016/j.cellsig.2010.10.015 20940046
71. TGFβ1-induced inflammation in precancerous epidermal squamous lesions requires IL-17. Mohammed J, Ryscavage A, Perez-Lorenzo R, Gunderson AJ, Blazanin N, Glick AB, J Invest Dermatol 2010 130 2295 2303 10.1038/jid.2010.92 20410912
72. Th17 cells in cancer: help or hindrance? Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W, Carcinogenesis 2011 32 643 649 10.1093/carcin/bgr019 21304053
73. IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Vykhovanets EV, Maclennan GT, Vykhovanets OV, Gupta S, Int J Clin Exp Pathol 2011 4 552 565 21904631
74. A novel population of Gr-1+-activated macrophages induced during acute toxoplasmosis. Mordue DG, Sibley LD, J Leukoc Biol 2003 74 1015 1025 10.1189/jlb.0403164 12972511 (Pubitemid 38040323)
75. Tumor cell-released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. Liu YY, Sun LC, Wei JJ, Li D, Yuan Y, Yan B, Liang ZH, Zhu HF, Xu Y, Li B, Song CW, Liao SJ, et al. J Immunol 2010 185 2773 2782 10.4049/jimmunol.1000772 20675592